Top

Published in:

01-10-2009 | Case Report

Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis

Authors: Rajiva Gupta, S. Deepanjali, M. M. Thabah, P. Kaur, S. Gupta

Published in: Rheumatology International | Issue 12/2009

Excerpt

Intravenous pulse cyclophosphamide is the standard therapy for the treatment of lupus nephritis [1]. Menstrual irregularities and premature ovarian failure can result from the prolonged use of cyclophosphamide [2, 3]. The teratogenic potential of cyclophosphamide has also been reported [4], and its effect has been proven in humans [5]. Its effect on pregnancy outcomes has not been studied well. We report a case of successful twin pregnancy during treatment with cyclophosphamide in a patient with lupus nephritis. …

Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950. doi:10.1002/art.1780340803 PubMedCrossRef

Wang CL, Wang F, Bosco JJ (1995) Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4:11–14. doi:10.1177/096120339500400103 PubMedCrossRef

Boumpas DT, Austin HA, Vaughan EM et al (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369PubMed

Enns GM, Roeder E, Chan RT et al (1999) Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86:237–241. doi:10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V PubMedCrossRef

Koren G, Pastuszak A, Ito S (1998) Drugs in pregnancy. N Engl J Med 338:1128–1137. doi:10.1056/NEJM199804163381607 PubMedCrossRef

Austin HA, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619PubMed

Park MC, Park YB, Jung SY et al (2004) Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13:569–574. doi:10.1191/0961203304lu1063oa PubMedCrossRef

Huong DL, Amoura Z, Duhaut P et al (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 9:2571–2576

Medeiros MM, Silveira VA, Menezes AP et al (2001) Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 34:1561–1568. doi:10.1590/S0100-879X2001001200008 PubMedCrossRef

10.

Mok CC, Lau CS, Wong RW (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41:831–837. doi:10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6 PubMedCrossRef

11.

Katsifis GE, Tzioufas AG (2004) Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 13:673–678. doi:10.1191/0961203304lu2012oa PubMedCrossRef

12.

Matsukawa Y, Nishinarita S, Horie T et al (1998) Successful child bearing during intravenous cyclophosphamide therapy in a patient with systemic lupus erythematosus. Br J Rheumatol 37:342–343. doi:10.1093/rheumatology/37.3.342 PubMedCrossRef

13.

Kart Koseoglu H, Yucel AE, Kunefeci G et al (2001) Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 10:818–820. doi:10.1177/096120330101001110 PubMedCrossRef

14.

Clowse ME, Magder L, Petri M (2005) Cyclophosphamide for lupus during pregnancy. Lupus 14:593–597. doi:10.1191/0961203305lu2169oa PubMedCrossRef

15.

Zemlickis D, Lishner M, Erlich R et al (1993) Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13:139–143. doi:10.1002/tcm.1770130304 PubMedCrossRef

Title: Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis
Authors: Rajiva Gupta
S. Deepanjali
M. M. Thabah
P. Kaur
S. Gupta
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 12/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-0860-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2009

Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin

Early onset neutropenia after mycophenolate mofetil in systemic sclerosis

IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system

Massive lower gastrointestinal haemorrhage, successfully treated with corticosteroids, as main symptom of Schönlein-Henoch purpura

Two distinct patterns of ankylosing spondylitis in Moroccan patients

Serum homocysteine level in patients with ankylosing spondylitis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage